IVB502

IVB502 is an adeno-associated virus (AAV)-based gene therapy being developed by InnoVec Biotherapeutics for the treatment of Duchenne Muscular Dystrophy (DMD). The therapy is designed to deliver a transgene encoding micro-dystrophin—a shortened, functional version of the dystrophin protein—to muscle cells. In patients with DMD, mutations in the DMD gene result in the absence of dystrophin, leading to progressive muscle weakness and wasting. By introducing the micro-dystrophin gene, IVB502 aims to restore muscle fiber integrity and improve motor function. The program is currently in the discovery stage, targeting systemic muscle delivery to address the underlying cause of the disease.